Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

Immunocore dosed the first patient in the first-in-human Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate, for HLA-A*02:01-positive patients with type 1 diabetes. IMC-S118AI is a bispecific designed to bind HLA-A*02:01 on beta cells and use PD-1 agonism to turn off autoreactive T cells, aiming to preserve insulin production. The dose escalation trial will assess safety, pharmacokinetics and clinical activity. Supporting preclinical data in human pancreas tissue slices, produced with the University of Florida, was recently published in Science Advances.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.